bpc-157 human studies dosing safety review Oral vs Injection: Benefits, Bioavailability & Recovery The Hidden Risks of BPC‑157:

HC Guayaba: Toms Gmez Gascn, Concepcin Vargas-Machuca Cabaero, M Isabel Gutirrez Snchez, M Angeles Fernndez Abad, Margarita Beltejar Rodrguez, Javier Martnez Suberviola, Miguel Angel Real Prez, Carmen Coello Alarcn, Carlos San Andrs Pascua, Jos Antonio Granados Garrido

By Saxophones Getting Louder

Please note that this cannot be used to make a diagnosis or initiate therapy

Only 11.2% of participants stopped the trial due to side effects, and the discontinuation rate dropped significantly after week 24, suggesting those who make it through the early phase generally tolerate it well long-term

A few select patients have reported they felt their results lasted as long as 2 years

For patients with genuinely adequate B12 status, the addition is unlikely to produce noticeable effects